You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

INTEGRILIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Integrilin patents expire, and what generic alternatives are available?

Integrilin is a drug marketed by Msd Sub Merck and is included in one NDA.

The generic ingredient in INTEGRILIN is eptifibatide. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the eptifibatide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Integrilin

A generic version of INTEGRILIN was approved as eptifibatide by TEVA PHARMS USA on June 12th, 2015.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for INTEGRILIN?
  • What are the global sales for INTEGRILIN?
  • What is Average Wholesale Price for INTEGRILIN?
Summary for INTEGRILIN
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 70
Clinical Trials: 16
Patent Applications: 3,909
Drug Prices: Drug price information for INTEGRILIN
What excipients (inactive ingredients) are in INTEGRILIN?INTEGRILIN excipients list
DailyMed Link:INTEGRILIN at DailyMed
Drug patent expirations by year for INTEGRILIN
Drug Prices for INTEGRILIN

See drug prices for INTEGRILIN

Recent Clinical Trials for INTEGRILIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Baylor College of MedicinePhase 1/Phase 2
Sisse R. Ostrowski, MD PhD DMScPhase 2
University of Alabama at BirminghamPhase 2

See all INTEGRILIN clinical trials

Paragraph IV (Patent) Challenges for INTEGRILIN
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
INTEGRILIN Injection eptifibatide 2 mg/mL, 100 mL vial 020718 1 2008-12-18
INTEGRILIN Injection eptifibatide 2 mg/mL, 10 mL vial 020718 1 2008-09-30

US Patents and Regulatory Information for INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Sub Merck INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for INTEGRILIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Sub Merck INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-001 May 18, 1998 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 ⤷  Sign Up ⤷  Sign Up
Msd Sub Merck INTEGRILIN eptifibatide INJECTABLE;INJECTION 020718-002 May 18, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for INTEGRILIN

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Accord Healthcare S.L.U. Eptifibatide Accord eptifibatide EMEA/H/C/004104
Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty).
Authorised yes no no 2016-01-11
GlaxoSmithKline (Ireland) Limited Integrilin eptifibatide EMEA/H/C/000230
Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes.Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).
Authorised no no no 1999-07-01
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for INTEGRILIN

See the table below for patents covering INTEGRILIN around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2156468 METHOD OF ASSAY OF PRESENCE OR ABSENCE OF INHIBITORY ACTIVITY OF PLATELET AGGREGATION (PA1), PURIFIED AND ISOLATED INHIBITOR OF PLATELET ACTIVITY (PA1) AND/OR ITS TRUNCATED FORM, METHOD OF PURIFICATION OF PA1 FROM SNAKE VENOM, PHARMACEUTICAL COMPOSITION FOR PREVENTION OF THROMBUS FORMATION, METHOD OF INHIBITION OF THROMBUS FORMATION ⤷  Sign Up
Canada 2636421 UNE METHODE DE STOCKAGE DE PLAQUETTES ET DE SANG ENTIER (A METHOD OF PLATELET AND WHOLE BLOOD STORAGE) ⤷  Sign Up
Netherlands 990043 ⤷  Sign Up
Luxembourg 90488 ⤷  Sign Up
South Korea 0180918 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for INTEGRILIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0477295 C990043 Netherlands ⤷  Sign Up PRODUCT NAME: EPTIFIBATIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 - EU/1/99/109/002 19990701; FIRST REGISTRATION: CH 54050, 54054 19970227
0477295 51/1999 Austria ⤷  Sign Up PRODUCT NAME: EPTIFIBATID ODER PHARMAZEUTISCH ANNEHMBARE SALZE HIEVON; NAT. REGISTRATION NO/DATE: EU/1/99/109/001 EU/1/99/109/002 19990701; FIRST REGISTRATION: LI 54050 UND 54054 19970227
0477295 SPC/GB99/046 United Kingdom ⤷  Sign Up PRODUCT NAME: EPTIFIBATIDE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: CH 54054 19970227; CH 54050 19970227; UK EU/1/99/109/001 19990701; UK EU/1/99/109/002 19990701
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.